BillionToOne, Inc.BLLNEarnings & Financial Report
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Revenue
$45.1M
Gross Profit
$25.7M
Operating Profit
$7.7M
Net Profit
$-11.5M
Gross Margin
57.1%
Operating Margin
17.0%
Net Margin
-25.5%
YoY Growth
-53.1%
EPS
$-1.13
BillionToOne, Inc. Q4 FY2024 Financial Summary
BillionToOne, Inc. reported revenue of $45.1M (down 53.1% YoY) for Q4 FY2024, with a net profit of $-11.5M (down 292.0% YoY) (-25.5% margin). Cost of goods sold was $19.4M, operating expenses totaled $18.1M.
Key Financial Metrics
| Total Revenue | $45.1M |
|---|---|
| Net Profit | $-11.5M |
| Gross Margin | 57.1% |
| Operating Margin | 17.0% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
BillionToOne, Inc. Q4 FY2024 revenue of $45.1M breaks down across 3 segments, led by Prenatal at $43.2M (95.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Prenatal | $43.2M | 95.8% |
| Other | $1.1M | 2.4% |
| Clinical Trial Support and Other Services | $800.0K | 1.8% |
BillionToOne, Inc. Revenue by Segment — Quarterly Trend
BillionToOne, Inc. revenue by segment across the last 3 reported quarters, showing how each business line (such as Prenatal and Other) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q4 FY2024 | Q3 FY2024 |
|---|---|---|---|
| Prenatal | $74.1M | $43.2M | — |
| Other | — | $1.1M | — |
| Clinical Trial Support and Other Services | — | $800.0K | — |
BillionToOne, Inc. Quarterly Revenue & Net Profit History
BillionToOne, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $83.5M | +117.4% | $5.7M | 6.8% |
| Q4 FY2024 | $45.1M | -53.1% | $-11.5M | -25.5% |
| Q3 FY2024 | $38.4M | — | $-14.9M | -38.8% |
Income Statement
| Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|
| Revenue | $38.4M | $45.1M | $83.5M |
| YoY Growth | N/A | -53.1% | 117.4% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|
| Assets | N/A | $302.1M | $327.5M |
| Liabilities | N/A | $134.3M | $147.6M |
| Equity | $-242.9M | $-251.7M | $-239.5M |
Cash Flow
| Q3 2025 | |
|---|---|
| Operating CF | $13.8M |